Follistatin-Like 1 Is an Akt-Regulated Cardioprotective Factor That Is Secreted by the Heart

Background— The Akt protein kinase is an important mediator of cardiac myocyte growth and survival. To identify factors with novel therapeutic applications in cardiac diseases, we focused on the identification of factors secreted from Akt1-activated cells that have cardioprotective effects through autocrine/paracrine mechanisms. Methods and Results— Using an inducible Akt1 transgenic mouse model, we have found that follistatin-like 1 (Fstl1) protein and transcript expression are increased 4.0- and 2.0-fold, respectively, by Akt activation in the heart (P<0.05). Fstl1 transcript was also upregulated in response to myocardial stresses including transverse aortic constriction, ischemia/reperfusion injury, and myocardial infarction. Adenovirus-mediated overexpression of Fstl1 protected cultured neonatal rat ventricular myocytes from hypoxia/reoxygenation-induced apoptosis (P<0.01), and this protective effect was dependent on the upregulation of both Akt and ERK activities. Conversely, knockdown of Fstl1 in cardiac myocytes decreased basal Akt signaling and increased the frequency of apoptotic death in vitro (P<0.01). The intravenous administration of an adenoviral encoding Fstl1 to mice resulted in a 66.0% reduction in myocardial infarct size after ischemia/reperfusion injury that was accompanied by a 70.9% reduction in apoptosis in the heart (P<0.01). Conclusions— These results indicate that Fstl1 is a cardiac-secreted factor that functions as an antiapoptotic protein. Fstl1 could play a role in myocardial maintenance and repair in response to harmful stimuli.

[1]  S. Houser,et al.  Pim-1 regulates cardiomyocyte survival downstream of Akt , 2006, Nature Medicine.

[2]  Y. Taniyama,et al.  Elevated myocardial Akt signaling ameliorates doxorubicin-induced congestive heart failure and promotes heart growth. , 2002, Journal of molecular and cellular cardiology.

[3]  K. Tsuchida,et al.  Expression of a TGF-beta1 inducible gene, TSC-36, causes growth inhibition in human lung cancer cell lines. , 2000, Cancer letters.

[4]  Orton,et al.  INTRAVENOUS NESIRITIDE, A NATRIURETIC PEPTIDE, IN THE TREATMENT OF DECOMPENSATED CONGESTIVE HEART FAILURE , 2000 .

[5]  R. Kitsis,et al.  The MEK1–ERK1/2 signaling pathway promotes compensated cardiac hypertrophy in transgenic mice , 2000, The EMBO journal.

[6]  Y. Fujio,et al.  Bone Morphogenetic Protein-2 Inhibits Serum Deprivation-induced Apoptosis of Neonatal Cardiac Myocytes through Activation of the Smad1 Pathway* , 2001, The Journal of Biological Chemistry.

[7]  N. Minamino,et al.  Cloning and sequence analysis of cDNA encoding a precursor for human brain natriuretic peptide. , 1988, Biochemical and biophysical research communications.

[8]  S. Engelhardt,et al.  A Secretion Trap Screen in Yeast Identifies Protease Inhibitor 16 as a Novel Antihypertrophic Protein Secreted From the Heart , 2007, Circulation.

[9]  S. Houser,et al.  Nuclear Targeting of Akt Enhances Ventricular Function and Myocyte Contractility , 2005, Circulation research.

[10]  S. Cook,et al.  Myostatin Regulates Cardiomyocyte Growth Through Modulation of Akt Signaling , 2006, Circulation research.

[11]  W. Van Hul,et al.  Extracellular regulation of BMP signaling in vertebrates: a cocktail of modulators. , 2002, Developmental biology.

[12]  Masahiro Ito,et al.  Akt3 overexpression in the heart results in progression from adaptive to maladaptive hypertrophy. , 2005, Journal of molecular and cellular cardiology.

[13]  J. Ingwall,et al.  Paracrine action accounts for marked protection of ischemic heart by Akt-modified mesenchymal stem cells , 2005, Nature Medicine.

[14]  T. Flynn,et al.  The amino acid sequence of an atrial peptide with potent diuretic and natriuretic properties. , 1983, Biochemical and biophysical research communications.

[15]  R. Kloner,et al.  Alterations in myostatin expression are associated with changes in cardiac left ventricular mass but not ejection fraction in the mouse. , 2007, The Journal of endocrinology.

[16]  Robert H Christenson,et al.  National Academy of Clinical Biochemistry Laboratory Medicine practice guidelines: Clinical utilization of cardiac biomarker testing in heart failure. , 2007, Circulation.

[17]  Y. Fujio,et al.  Isolation and characterization of the murine cardiotrophin-1 gene: expression and norepinephrine-induced transcriptional activation. , 2000, Journal of molecular and cellular cardiology.

[18]  H. Drexler,et al.  The Transforming Growth Factor-&bgr; Superfamily Member Growth-Differentiation Factor-15 Protects the Heart From Ischemia/Reperfusion Injury , 2006 .

[19]  I. Shiojima,et al.  Microarray analysis of Akt1 activation in transgenic mouse hearts reveals transcript expression profiles associated with compensatory hypertrophy and failure. , 2006, Physiological genomics.

[20]  R. Califf,et al.  Prognostic Value of Growth-Differentiation Factor-15 in Patients With Non–ST-Elevation Acute Coronary Syndrome , 2007, Circulation.

[21]  R. Kitsis,et al.  Akt promotes survival of cardiomyocytes in vitro and protects against ischemia-reperfusion injury in mouse heart. , 2000, Circulation.

[22]  P. Ponikowski,et al.  Prognostic utility of growth differentiation factor-15 in patients with chronic heart failure. , 2007, Journal of the American College of Cardiology.

[23]  S. Cook,et al.  Phenotypic Spectrum Caused by Transgenic Overexpression of Activated Akt in the Heart* , 2002, The Journal of Biological Chemistry.

[24]  R. Kitsis,et al.  Intracoronary, adenovirus-mediated Akt gene transfer in heart limits infarct size following ischemia-reperfusion injury in vivo. , 2000, Journal of molecular and cellular cardiology.

[25]  K. Nose,et al.  Decrease in the expression of a novel TGF beta1-inducible and ras-recision gene, TSC-36, in human cancer cells. , 1997, Cancer letters.

[26]  T. Abraham,et al.  Myostatin does not regulate cardiac hypertrophy or fibrosis , 2007, Neuromuscular Disorders.

[27]  I. Shiojima,et al.  Disruption of coordinated cardiac hypertrophy and angiogenesis contributes to the transition to heart failure. , 2005, The Journal of clinical investigation.

[28]  K. Patel,et al.  Developmental expression of myostatin in cardiomyocytes and its effect on foetal and neonatal rat cardiomyocyte proliferation. , 2007, Cardiovascular research.

[29]  J. Ross,et al.  Akt induces enhanced myocardial contractility and cell size in vivo in transgenic mice , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[30]  I. Shiojima,et al.  Vascular Endothelial Growth Factor Blockade Promotes the Transition From Compensatory Cardiac Hypertrophy to Failure in Response to Pressure Overload , 2006, Hypertension.

[31]  T. Hewett,et al.  GDF15/MIC-1 Functions As a Protective and Antihypertrophic Factor Released From the Myocardium in Association With SMAD Protein Activation , 2006, Circulation research.

[32]  Ronald J Moore,et al.  Human plasma N-glycoproteome analysis by immunoaffinity subtraction, hydrazide chemistry, and mass spectrometry. , 2005, Journal of proteome research.

[33]  T. Yue,et al.  Inhibition of extracellular signal-regulated kinase enhances Ischemia/Reoxygenation-induced apoptosis in cultured cardiac myocytes and exaggerates reperfusion injury in isolated perfused heart. , 2000, Circulation research.

[34]  D. Das,et al.  Retracted: Cardioprotective effect of resveratrol via HO-1 expression involves p38 map kinase and PI-3-kinase signaling, but does not involve NFκB , 2006 .

[35]  A. D. de Bold,et al.  A rapid and potent natriuretic response to intravenous injection of atrial myocardial extract in rats. Reprinted from Life Sci. 28:89-94, 1981. , 2001, Journal of the American Society of Nephrology : JASN.

[36]  S. Kihara,et al.  Adiponectin accumulates in myocardial tissue that has been damaged by ischemia-reperfusion injury via leakage from the vascular compartment. , 2007, Cardiovascular research.

[37]  H. Drexler,et al.  The transforming growth factor-beta superfamily member growth-differentiation factor-15 protects the heart from ischemia/reperfusion injury. , 2006, Circulation research.

[38]  K. Kangawa,et al.  Adrenomedullin: a possible autocrine or paracrine inhibitor of hypertrophy of cardiomyocytes. , 1998, Hypertension.

[39]  Y. Ahn,et al.  Nuclear Targeting of Akt Enhances Kinase Activity and Survival of Cardiomyocytes , 2003, Circulation research.

[40]  G. Semenza,et al.  Complete loss of ischaemic preconditioning-induced cardioprotection in mice with partial deficiency of HIF-1 alpha. , 2008, Cardiovascular research.

[41]  I. Shiojima,et al.  Regulation of cardiac growth and coronary angiogenesis by the Akt/PKB signaling pathway. , 2006, Genes & development.

[42]  K. Tsuchida,et al.  Expression of a TGF-β1 inducible gene, TSC-36, causes growth inhibition in human lung cancer cell lines , 2000 .

[43]  N. Minamino,et al.  Cloning and sequence analysis of cDNA encoding a precursor for porcine brain natriuretic peptide. , 1988, Biochemical and biophysical research communications.

[44]  J. Vass,et al.  Regulation of a multigenic invasion programme by the transcription factor, AP-1: re-expression of a down-regulated gene, TSC-36, inhibits invasion , 2000, Oncogene.

[45]  A. D. de Bold,et al.  A rapid and potent natriuretic response to intravenous injection of atrial myocardial extract in rats. , 1981, Life sciences.